Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C569- Malignant neoplasm of unspecifiedovary Health Condition 3: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: Tablet duloxetine: It is single arm study and I will give tablet duloxetine 30 mg of for first week then 60 mg of for 3 months to patients who are receiving paclitaxel from first cycle
Sponsors
Stanley medical College and hospital
Eligibility
Inclusion criteria
Inclusion criteria: All patients recieving paclitaxel with any Cancer diagnosis with any stage will and able to comply with all study requirements with signed and written consent
Exclusion criteria
Exclusion criteria: Concurrent disease that may lead to peripheral neuropathy like diabetes mellitus rheumatologic disease vitamin B12 deficiency any allergy to duloxetine patients receiving ccb alfa blocker with psychiatric disorders any bleeding manifestations and pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effect of duloxetine in the prevention of chemotherapy induced peripheral neuropathy in patients receiving paclitaxelTimepoint: 12 WEEKS | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare dose modification of paclitaxel due to peripheral neuropathy in each armTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr PN Sathiyamoorthy
Stanley medical College and hospital
Outcome results
None listed